Short Interest in RemeGen Co., Ltd. (OTCMKTS:REGMF) Drops By 24.5%

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 147,028 shares, a drop of 24.5% from the December 15th total of 194,690 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is presently 735.1 days. Based on an average daily volume of 200 shares, the days-to-cover ratio is presently 735.1 days.

RemeGen Stock Performance

OTCMKTS REGMF opened at $9.81 on Friday. The company has a 50-day simple moving average of $10.36 and a two-hundred day simple moving average of $8.26. RemeGen has a 12-month low of $9.81 and a 12-month high of $15.91.

RemeGen Company Profile

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.